CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice

[1]  D. RiordanJesse.  Re: Srivastava A, Carter BJ; AAV Infection: Protection from Cancer; Hum Gene Ther 2017;28:323–327; DOI: 10.1089/hum.2016.147 , 2017 .

[2]  SrivastavaArun,et al.  AAV Infection: Protection from Cancer. , 2017 .

[3]  Edward M. Callaway,et al.  In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration , 2016, Nature.

[4]  Li-Yao Zhu,et al.  CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles , 2016, Molecular therapy. Nucleic acids.

[5]  Mingyao Liu,et al.  CRISPR/Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse , 2016, EMBO molecular medicine.

[6]  Steve D. M. Brown,et al.  Correction of the auditory phenotype in C57BL/6N mice via CRISPR/Cas9-mediated homology directed repair , 2016, Genome Medicine.

[7]  John M. Shelton,et al.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.

[8]  George M. Church,et al.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.

[9]  Dongsheng Duan,et al.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.

[10]  Supriya V. Vartak,et al.  Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing , 2015, The FEBS journal.

[11]  Wenyan Jiang,et al.  CRISPR-Cas: New Tools for Genetic Manipulations from Bacterial Immunity Systems. , 2015, Annual review of microbiology.

[12]  Y. Doyon,et al.  In vivo genome editing of the albumin locus as a platform for protein replacement therapy. , 2015, Blood.

[13]  I. Alexander,et al.  Adeno-associated virus serotypes for gene therapeutics. , 2015, Current opinion in pharmacology.

[14]  A. Regev,et al.  Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System , 2015, Cell.

[15]  T. Ohmori,et al.  New approaches to gene and cell therapy for hemophilia , 2015, Journal of thrombosis and haemostasis : JTH.

[16]  S. Milstein,et al.  An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia , 2015, Nature Medicine.

[17]  Natalia N. Ivanova,et al.  Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells , 2015, Nature Biotechnology.

[18]  E. Lanphier,et al.  Don’t edit the human germ line , 2015, Nature.

[19]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[20]  Hidde L Ploegh,et al.  Inhibition of non-homologous end joining increases the efficiency of CRISPR/Cas9-mediated precise [TM: inserted] genome editing , 2015, Nature Biotechnology.

[21]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[22]  T. Ohmori,et al.  The prevalence of neutralizing antibodies against adeno‐associated virus capsids is reduced in young Japanese individuals , 2014, Journal of medical virology.

[23]  F. Zhang,et al.  CRISPR/Cas9 for genome editing: progress, implications and challenges. , 2014, Human molecular genetics.

[24]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[25]  S. Jentsch,et al.  Mechanisms and principles of homology search during recombination , 2014, Nature Reviews Molecular Cell Biology.

[26]  Y. Doyon,et al.  Robust ZFN-mediated genome editing in adult hemophilic mice. , 2013, Blood.

[27]  G. Church,et al.  Cas9 as a versatile tool for engineering biology , 2013, Nature Methods.

[28]  C. Miller,et al.  The CDC Hemophilia B mutation project mutation list: a new online resource , 2013, Molecular genetics & genomic medicine.

[29]  David R. Liu,et al.  High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity , 2013, Nature Biotechnology.

[30]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[31]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[32]  T. Ohmori,et al.  Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  G. Young.  New challenges in hemophilia: long-term outcomes and complications. , 2012, Hematology. American Society of Hematology. Education Program.

[34]  David V Schaffer,et al.  The AAV Vector Toolkit: Poised at the Clinical Crossroads. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  Lili Wang,et al.  Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector. , 2012, Human gene therapy.

[36]  Hojun Li,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[37]  Tomoko Matsumoto,et al.  A modified thrombin generation test for investigating very low levels of factor VIII activity in hemophilia A , 2009, International journal of hematology.

[38]  Alan R. Cohen,et al.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. , 2007, The New England journal of medicine.

[39]  Theresa A. Storm,et al.  Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo , 2001, Journal of Virology.

[40]  A. Srivastava,et al.  AAV Infection: Protection from Cancer. , 2017, Human gene therapy.

[41]  F. Gleason,et al.  Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA , 2014 .